Literature DB >> 7960226

Hepatic tumors induced by carbon tetrachloride in transgenic mice carrying a human c-H-ras proto-oncogene without mutations.

S Tsunematsu1, H Saito, T Kagawa, T Morizane, J Hata, T Nakamura, H Ishii, M Tsuchiya, T Nomura, M Katsuki.   

Abstract

Hepatic tumors were generated in mice by repeated administration of carbon tetrachloride (CCl4). Eight transgenic (Tg) mice carrying a human c-H-ras proto-oncogene (rasH2 line) and 9 non-Tg mice were killed at 20 weeks. Tg mice developed more tumors than did non-Tg littermates. Most tumors were neoplastic nodules, but 1 hepatocellular carcinoma (HCC) was found in a Tg mouse at 20 weeks. Three Tg and 2 non-Tg mice were kept without further administration of CCl4. Two Tg mice died at 30 weeks of HCC with intra-abdominal bleeding, and 1 Tg mouse developed HCC with a mesenteric metastasis at 32 weeks. No HCC was found in 2 non-Tg mice at 32 weeks. Although mutations at codon 12, 13, and 61 of the H-ras gene are often found in murine hepatocarcinogenesis, neither the tumors, including one HCC, nor the normal cells revealed any such mutations. These results showed that the unmutated human c-H-ras gene facilitates malignant transformation of hepatocytes when continuous liver-cell death and regeneration is caused by repeated administration of CCl4.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7960226     DOI: 10.1002/ijc.2910590420

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  2 in total

Review 1.  The role of wild type RAS isoforms in cancer.

Authors:  Bingying Zhou; Channing J Der; Adrienne D Cox
Journal:  Semin Cell Dev Biol       Date:  2016-07-13       Impact factor: 7.727

2.  Rare activation of the human c-Ha-ras transgene of mice in hemangioendothelial sarcomas and liver tumors induced by Glu-P-1.

Authors:  R Inoue; T Ushijima; M Katami; H Kushida; K Wakabayashi; H Sato; M Asamoto; M Katsuki; T Sugimura; M Nagao
Journal:  Jpn J Cancer Res       Date:  1996-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.